Annovis Bio (ANVS) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Annovis Bio (NYSE: ANVS) in the last few weeks:

• 7/9/2026 – Annovis Bio was upgraded by Zacks Research to “hold”.
• 7/7/2026 – Annovis Bio is now covered by Roth Capital. They set a “buy” rating and a $8.00 price target on the stock.
• 7/7/2026 – Annovis Bio was upgraded by Roth Capital to “strong-buy”.
• 7/6/2026 – Annovis Bio was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Buying and Selling at Annovis Bio

In related news, Director Michael B. Hoffman purchased 76,344 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $1.87 per share, with a total value of $142,763.28. Following the acquisition, the director owned 3,364,883 shares in the company, valued at approximately $6,292,331.21. This trade represents a 2.32% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 20.80% of the company’s stock.

Annovis Bio, Inc (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions.

The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients.